Recombinant Cynomolgus Monkey LDLR His-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11151-LD

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11151-LD-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

XP_005588053.1

Conjugate

Unconjugated

Applications

Bioactivity

View all LDLR Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived cynomolgus monkey LDLR protein
Ala22-Gly788, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala22

Predicted Molecular Mass

86 kDa

SDS-PAGE

125-140 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Human LDL is immobilized at 4.00 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey LDLR His-tag (Catalog # 111151-LD) binds with an ED50 of 30.0-300 ng/mL.

Scientific Data Images for Recombinant Cynomolgus Monkey LDLR His-tag Protein, CF

Recombinant Cynomolgus Monkey LDLR His-tag Protein Binding Activity.

When Human LDL is immobilized at 4.00 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey LDLR His-tag Protein (Catalog # 11151-LD) binds with an ED50 of 30.0-300 ng/mL.

Recombinant Cynomolgus Monkey LDLR His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant Cynomolgus Monkey LDLR His-tag Protein (Catalog # 11151-LD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 125-140 kDa.

Formulation, Preparation and Storage

11151-LD
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 200 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LDLR

The low density lipoprotein receptor (LDLR) is the founding member of the LDLR family, a group of widely expressed type I transmembrane glycoprotein cell surface scavenger receptors (1-5). Members of the family are endocytic receptors which bind and internalize extracellular ligands, including lipoproteins, exotoxins, and lipid-carrier complexes but can also co-regulate adjacent cell-surface signaling molecules (3, 4). Mature LDLR consists of an extracellular domain (ECD) with 7 cysteine-rich complement-like repeats (class A LDL domains), calcium-binding EGF repeats, and beta ‑propeller structures (class B LDL repeats), a transmembrane domain and a cytoplasmic domain with an NPxY-repeat motif. The ECD of cynomologus LDLR shares 94% amino acid sequence identity with human LDLR. LDLR is constitutively and widely expressed and plays a key role in regulating cholesterol homeostasis. The class A LDL domains near the N-terminus of LDLR bind apoB and apoE, the apolipoproteins of low- and very low-density lipoproteins (LDL and VLDL), respectively (1, 2, 4, 7). Hepatocyte LDLR is responsible for endocytosis and clearing of most plasma LDL cholesterol from circulation (2, 7). At the low pH of the endocytic vesicle, it dissociates, allowing degradation of LDL and recycling of LDLR to the cell surface (1, 4). Lack of LDLR expression or function causes familial hypercholesterolemia (FH) and leads to premature cardiovascular disease (4, 7, 8). The protease PCSK9 (proprotein convertase subtilisin/kexin type 9) can also cause increased plasma cholesterol by promoting LDLR degradation rather than recycling to the cell surface (8-10). Additionally, soluble forms of LDLR are reported to be released by phorbol esters or interferons and could serve as a disease marker (5, 11, 12). Several studies have demonstrated a role for LDLR in cancer progression, including liver cancer, leukemia, lung cancer, breast cancer, colorectal cancer, and prostate cancer (13).

References

  1. Go, G.W. and A. Mani (2012) Yale J. Biol. Med. 85:19.
  2. Ren, G. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1059.
  3. Bujo, H. and Y. Saito (2006) Arterioscler. Thromb. Vasc. Biol. 26:1246.
  4. Gent, J. and I. Braakman (2004) Cell. Mol. Life Sci. 61:2461.
  5. Begg, M.J. et al. (2004) Eur. J. Biochem. 271:524.
  6. Stolt, P.C. and H.H. Bock (2006) Cell. Signal. 18:1560.
  7. Defesche, J.C. (2004) Semin. Vasc. Med. 4:5.
  8. De Castro-Oros, I. et al. (2010) Appl. Clin Genet. 3:53.
  9. Zhang, D.W. et al. (2008) Proc. Natl. Acad. Sci. U.S.A. 105:13045.
  10. Tavori, H. et al. (2013) Circulation 127:2403.
  11. Fischer, D.G. et al. (1993) Science 262:250.
  12. Mbikay, M. et al. (2020) Lipids Health Dis 19:17
  13. Roslan, Z. et al. (2019) J. Oncol. 2019:536302.

Long Name

Low Density Lipoprotein Receptor

Alternate Names

LDL R

Entrez Gene IDs

3949 (Human); 16835 (Mouse); 300438 (Rat); 396801 (Porcine); 102127361 (Cynomolgus Monkey)

Gene Symbol

LDLR

UniProt

XP_005588053.1

Additional LDLR Products

Product Documents for Recombinant Cynomolgus Monkey LDLR His-tag Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Cynomolgus Monkey LDLR His-tag Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.